Alvotech's Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan
yahoo.com
news
2022-10-17 09:00:00

Alvotech

REYKJAVIK, Iceland, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner Fuji Pharma Co., Ltd. ('Fuji') has submitted an application to the Japanese Ministry of Health, Labor and Welfare for marketing approval of the first biosimilar candidate developed under the companies' exclusive commercialization partnership.
